Testosterone Levels and Cutibacterium

Arthroplasty, Replacement, Shoulder Clinical Trial

Official title:

Association Between Serum Testosterone Levels and Cutibacterium Culture Positivity During Shoulder Arthroplasty

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05030220
• Other study ID #: STUDY00009200
• Status: Recruiting
• Start date: July 1, 2020
• Est. completion date: January 1, 2027

Study information

• Verified date: December 2023
• Source: University of Washington
• Contact: Jason E Hsu, MD
• Phone: 330-883-8829
• Email: jehsu[@]uw.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Phase 1: In 51 patients undergoing shoulder arthroplasties, total serum testosterone, free testosterone and sex hormone binding globulin levels obtained in the clinic before surgery were correlated with the levels of Cutibacterium on the skin in clinic, in the operating room prior to surgery, and in the skin incision. Phase 2: The investigators wish to determine if preoperative serum testosterone levels are associated with risk for shoulder PJI (periprosthetic joint infection) in patients undergoing primary shoulder arthroplasty. Also to determine if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.

Description:

Phase 1: 51 patients having elective shoulder arthroplasty were offered the opportunity to participate, consented and enrolled in this prospective clinical cohort study. At a preoperative clinic visit, basic demographic information was collected along with the patient's response to a question about taking supplemental testosterone. A swab of the unprepared skin over the area of the intended surgical incision was obtained and sent for culture. At this clinic visit, a sample of the patient's blood was also obtained and submitted to our clinical laboratory for the levels of total serum testosterone, sec hormone binding globulin (SHBG), and free testosterone. Immediately before surgery, another swab of the unprepared skin over the area of the intended surgical incision was once again obtained and sent for culture. After incision, a swab of the freshly incised dermis was obtained and sent for culture. All 3 swabs that were obtained were observed for 21 days. The investigators analyzed the cultures to determine the presence and load of bacteria using a semiquantitative method, known as the Cutibacterium specimen value (SpCuV) Phase 2: This phase will also involve a onetime pre-operative testosterone serum test. If the subject consents to participate, this additional sample of blood will be collected for a testosterone serum test during the routine pre-operative blood draw that all patients have before a shoulder arthroplasty regardless of research participation. The investigators will include cultures such as skin swabs taken at pre-operative clinic appointments, skin swabs taken at the time of surgery, incision swabs taken at the time of surgery, and discarded tissue from surgery using our standard protocol for specimens. For this study's outcome measures, the investigators will record the culture results from those clinical specimens and compare them to the testosterone serum test. Some subjects may also be a part of a long term follow-up study and the follow-up data (self-reported outcome measures, etc.) from that study will be included for analysis for those patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: January 1, 2027
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Phase 1 Inclusion Criteria:

• Patients having elective shoulder arthroplasty

Phase 1 Exclusion Criteria:

• history of shoulder septic arthritis
• antibiotic use within 3 months prior to surgery
• recent treatment for acne
• Lacked fluency in English

Phase 2 Inclusion Criteria:

• Patients having elective shoulder arthroplasty

Phase 2 Exclusion Criteria:

• Lacked fluency in English

Related Conditions & MeSH terms

• Arthroplasty, Replacement, Shoulder

Locations

Country	Name	City	State
United States	University of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum testosterone		At pre-operative clinic appointment, typically within 30 days prior to surgery
Primary	Free testosterone		At pre-operative clinic appointment, typically within 30 days prior to surgery
Primary	sex hormone binding globulin		At pre-operative clinic appointment, typically within 30 days prior to surgery
Primary	Cutibacterium specimen value		Skin swab at pre-operative clinic appointment, typically within 30 days prior to surgery
Primary	Cutibacterium specimen value		Skin swab immediately pre-operative
Primary	Cutibacterium specimen value		Freshly incised dermis of surgical wound
Primary	Preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty.		Up to 20 years after surgery
Primary	Preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty		21 days after surgery